The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy

<div>SBRT plans for brain metastasis patient. The patient was a 59-year-old female with adenocarcinoma stage II NSCLC with brain metastases in the right occipital lobe.</div>

Mediators of Inflammation

fig2

Figure 2

Figure 2: The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy 

Figure 2 | The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy 